Significant Accounting Policies (Narrative) (Details)			12 Months Ended
	May 09, 2019 USD ($)	Jan. 01, 2019 USD ($)	Dec. 31, 2019 USD ($) $ / shares shares	Dec. 31, 2018 USD ($) $ / shares shares	Dec. 05, 2019
Impairment of long-lived assets			$ 0
Acquired IPR&D expense				$ 5,691,000
Impairment of in-process research and development			0
Unrecognized tax benefits			$ 0	$ 0
Conversion ratio of reverse stock split	0.0714		0.0714
Common stock, par value (in dollars per share) | $ / shares			$ 0.01	$ 0.01
Common stock, shares authorized | shares			217,000,000	217,000,000
Derivative liability, fair value	$ 2,900,000			$ 1,117,000
Lease liability			$ 2,863,000
Right-of-use asset			2,028,000
Goodwill, Impairment Loss			$ 0
Armata Biotehnološke Raziskave in Razvoj d o o [Member]
Percentage of ownership sold					100.00%
Measurement Input, Discount Rate [Member]
IPR&D measurement input			17.3
Australian Taxation Office [Member]
Tax rebates received			$ 1,300,000
Accounting Standards Update 2016-02 [Member]
Estimated incremental borrowing rate (as a percent)		15.00%
Accounting Standards Update 2016-02 [Member] | Restatement Adjustment [Member]
Lease liability		$ 3,800,000
Right-of-use asset		2,700,000
Cumulative effect on accumulated deficit		$ 0